# Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)

> **NCT04316143** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 33 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Oral zamicastat

## Key facts

- **NCT ID:** NCT04316143
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-10-20
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04316143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04316143, "Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04316143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*